Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

CV; the remaining eight patients tested positive for HCV, at an average of two years following the completion of treatment. The study found that these eight patients exhibited no consistency in age, gender or HCV genotype, and it has not been determined if these patients experienced a relapse or if they were re-infected with HCV.

"We at Roche are proud to be able to offer some hepatitis C patients the prospect of such a positive outcome with our currently-available therapies, but we also recognize the urgent need to further improve response rates," said Tom Klein, Vice President, Hepatology, Roche. "In addition to ongoing research with PEGASYS, Roche has the most comprehensive pipeline in the area, with four compounds currently in human development that target the virus in a number of different ways. The development of R1626 and partnerships with InterMune, Maxygen and Pharmasset, all underscore our long-term commitment to finding effective new therapies with the goal of successfully treating more patients with chronic hepatitis C."

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS, are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the ... Lilly and Company (NYSE: LLY ), Nektar Therapeutics ... ), and Novartis AG (NYSE: NVS ). Free ... http://investor-edge.com/register . On Friday, December 12, 2014, the ... Industrial Average lost 1.79%, to finish the day at 17,280.83, ...
(Date:12/15/2014)... 2014   DaVita HealthCare Partners Inc.  (NYSE: ... largest and most innovative health care communities, today ... DaVita Clinical Research  (DCR) and  HealthCare Partners Clinical Research ... extensive clinical research and data analytics services, specifically ... end-stage renal disease (ESRD), as well as primary ...
(Date:12/14/2014)... 2014  ChartSpan, a consumer platform for patients managing ... iPad medical app in the United States ... ChartSpan is an iPhone and iPad ... and send electronic healthcare records. The product was built ... of waiting for the healthcare system to deliver on ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3
(Date:12/17/2014)... Unidesk Corporation today announced that ... welcomed its inaugural class in August 2013, has ... support bring your own device (BYOD) and deliver ... The solution, comprised of Citrix XenDesktop ... and storage infrastructure and Unidesk virtual ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
(Date:12/17/2014)... 17, 2014 In its comprehensive analysis ... its Argus Claim Review division have recently identified out-of-network ... common ways savings are achieved on behalf of employer-clients. ... of dollars in savings to Argus each year, with ... As explained by Tom Doney, Cypress president and CEO, ...
(Date:12/17/2014)... Now in its second year, the SeniorAdvisor.com ... best in senior living and home care across the ... and agencies that have received outstanding online feedback from ... 100,000 providers currently listed on SeniorAdvisor.com, only 879 were ... of 2015 Awards are located all over the country ...
(Date:12/17/2014)... -- As gas prices rose in recent years, so ... In times of gas increases, more people start ... the researchers explained. They examined data gathered between ... number of motorcycle registrations in the United States and ... analysis revealed a strong association between rising gas prices ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2
... Jan. 5 Hurricane Ike devastated the,Texas coast on ... surrounding cities are still without shelter. With the help ... now living in tents will be,able to stay warm ... On November 29, Brady Spears, Equal Health CEO ...
... China, Jan. 5 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC ... a leading,developer and distributor of prescription and over ... dietary supplements,medical devices and medical formulations, announced today ... Relations for a primary term of one year,commencing ...
... Jan. 5 MedCath Corporation,(Nasdaq: MDTH ... healthcare,services, predominately the diagnosis and treatment of cardiovascular ... its ownership in a joint venture,in its MedCath ... quarter earnings call on November 13, 2008, that ...
... 5 In 2008, Laura Plummer made enough New,Year,s ... Plummer quit smoking,started exercising, ate healthfully, lost 35 pounds, ... than 20 years, according to RealAge.com,s,patented test. , ... wonder "The Oprah Winfrey Show" came,calling. On Tuesday, January ...
... MARIETTA, Ga., Jan. 5 Nine out of 10 ... husband or male partner,experiences symptoms like fatigue, depressed mood ... known as low testosterone, or Low T, according,to survey ... to talk to their husbands or boyfriends about making ...
... Lumenis announces 510(k) approval for the new AcuPulse ... Jan. 5 Lumenis Inc., a global ... radiofrequency devices for surgical, aesthetic, and ophthalmic applications, ... of its new AcuPulse CO2 Laser for ENT, ...
Cached Medicine News:Health News:Staying Warm with the Help of Equal Health 2Health News:China Medicine Renews Contract with CCG Investor Relations 2Health News:China Medicine Renews Contract with CCG Investor Relations 3Health News:MedCath Corporation Announces Completion of Sale of Equity Interest in Joint Venture 2Health News:Taking 20 Years Off Her Health and Looks, RealAge Member Flaunts It on 'Oprah' Show 2Health News:New Initiative Urges Women to Address Men's Health this New Year 2Health News:New Initiative Urges Women to Address Men's Health this New Year 3Health News:New Initiative Urges Women to Address Men's Health this New Year 4Health News:New Initiative Urges Women to Address Men's Health this New Year 5Health News:An Evolution in Automated CO2 Laser Surgery 2
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
One piece, 100% fused silica construction offers low scatter and high efficiency...
... truly lateral, all quartz fiber. The design ... technology for Total Internal Reflection (TIR) at ... output is virtually indistinguishable from an axial ... in a round spot of low divergence. ...
The new series of Steris Power-lift Stirrups incorporate all of the proven clinical benefits of Allen-style booted stirrups: maximum safety for the patient, ease of setup for your staff, impressive v...
Medicine Products: